**Mayo Clinic - Israel Health Tech R&D Program**

**Call for Proposals**

The *Israel Innovation Authority* and *Mayo Clinic* invite interested Israeli companies to submit applications for research and development projects in the healthcare-related technology field with Mayo Clinic.

This call is open to joint proposal for cooperation in R&D activities with Mayo Clinic.

Mayo Clinic and the Israel Innovation Authority are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the United States’ healthcare market.

Mayo Clinic would serve as a real-world living laboratory for the Israeli companies, where Mayo Clinic clinical and research experts would work with Israeli startups to test and improve existing processes, services, or products; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to the U.S., and advance the development and deployment of discoveries for the benefit of patients everywhere.

**The health themes of interest to Mayo Clinic include** digital, device, therapeutic or diagnostic technologies. Mayo Clinic has broad research and clinical interests and interested co-development projects in which it can add value to the company.

**Application Process**

**Phase 1**

**Deadline for Expression of Interest (EOI) form submissions: 14/11/2022**

**Phase 2**

By 22/02/2023 the Israel Innovation Authority will invite Mayo Clinic-selected Israeli companies to phase 2.

**Deadline for full submissions: 21/06/202****3**

**What support do the Innovation Authority and Mayo Clinic offer?**

Successful Israeli applicant companies will receive funding from the Israel Innovation Authority.

The Israel Innovation Authority can support R&D performing companies, registered and operating in Israel, with a grant of up to 50% of the approved R&D and Pilot Expenses Budget, according to its regulations and procedures. The Israeli companies must follow Israel Innovation Authority's rules and regulations, as described in the Hebrew website:

[**https://innovationisrael.org.il/international/rnd**](https://innovationisrael.org.il/international/rnd)

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

Mayo Clinic would provide assistance for the project and make it accessible through an applicable agreement with the selected Israeli companies. In the case of a pilot project, where no IP is shared, up to 10% of the project budget could be used to pay Mayo Clinic for its services. In the case of a joint R&D project, where IP is shared, the costs of Mayo Clinic could not be funded by the IIA.

An appropriate agreement between successful applicant companies and HHC will need to be signed as one of the first milestones during the project initiation.

**Process and Timeline**

|  |  |
| --- | --- |
| Program launch | September 2022 |
| Deadline for submission of Expression of Interest (EOI)  | 14/11/2022 |
| Health centers select shortlisted companies, IIA invites shortlisted applicants to submit full application | 22/02/2023 |
| Deadline for full IIA online application  | 21/06/2023 |
| IIA funding decision & project launch  | September 2023 |

**Contacts**

|  |  |
| --- | --- |
| **Mayo Clinic** Mayo-Israeli Start-up InitiativeEmail: mayoclinicventures@mayo.edu | **Israel Innovation Authority**International Collaborations DivisionInternationalCollaboration@innovationisrael.org.il |